Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in advanced hepatocellular carcinoma
NCT06822985Phase 1Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC). Primary endpoint: Median Progression-Free Survival at 1 year. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06822985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822985.